as 05-09-2025 4:00pm EST
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Upcoming Earnings Alert:
Get ready for potential market movements as Spero Therapeutics Inc. SPRO prepares to release earnings report on 13 May 2025.
Founded: | 2013 | Country: | United States |
Employees: | N/A | City: | CAMBRIDGE |
Market Cap: | 40.5M | IPO Year: | 2017 |
Target Price: | $5.00 | AVG Volume (30 days): | 113.5K |
Analyst Decision: | Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.27 | EPS Growth: | N/A |
52 Week Low/High: | $0.51 - $1.72 | Next Earning Date: | 05-13-2025 |
Revenue: | $47,977,000 | Revenue Growth: | -53.77% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
SPRO Breaking Stock News: Dive into SPRO Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
GlobeNewswire
11 days ago
Simply Wall St.
a month ago
Thomson Reuters StreetEvents
a month ago
GuruFocus.com
a month ago
Zacks
a month ago
GlobeNewswire
a month ago
GlobeNewswire
2 months ago
The information presented on this page, "SPRO Spero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.